Cargando…

Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science

BACKGROUND: Contemporary therapies for metastatic castration-resistant prostate cancer (mCRPC) have shown survival improvements, which do not account for patient experience and health-related quality of life (HRQoL). METHODS: This literature review included a search of MEDLINE for randomized clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Nussbaum, N, George, D J, Abernethy, A P, Dolan, C M, Oestreicher, N, Flanders, S, Dorff, T B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868871/
https://www.ncbi.nlm.nih.gov/pubmed/26832363
http://dx.doi.org/10.1038/pcan.2015.42
_version_ 1782432218006683648
author Nussbaum, N
George, D J
Abernethy, A P
Dolan, C M
Oestreicher, N
Flanders, S
Dorff, T B
author_facet Nussbaum, N
George, D J
Abernethy, A P
Dolan, C M
Oestreicher, N
Flanders, S
Dorff, T B
author_sort Nussbaum, N
collection PubMed
description BACKGROUND: Contemporary therapies for metastatic castration-resistant prostate cancer (mCRPC) have shown survival improvements, which do not account for patient experience and health-related quality of life (HRQoL). METHODS: This literature review included a search of MEDLINE for randomized clinical trials enrolling ⩾50 patients with mCRPC and reporting on patient-reported outcomes (PROs) since 2010. RESULTS: Nineteen of 25 publications describing seven treatment regimens (10 clinical trials and nine associated secondary analyses) met the inclusion criteria and were critically appraised. The most commonly used measures were the Functional Assessment of Cancer Therapy-Prostate (n=5 trials) and Brief Pain Inventory Short Form (n=4 trials) questionnaires. The published data indicated that HRQoL and pain status augmented the clinical efficacy data by providing a better understanding of treatment impact in mCRPC. Abiraterone acetate and prednisone, enzalutamide, radium-223 dichloride and sipuleucel-T offered varying levels of HRQoL benefit and/or pain mitigation versus their respective comparators, whereas three treatments (mitoxantrone, estramustine phosphate and docetaxel, and cabazitaxel) had no meaningful impact on HRQoL or pain. The main limitation of the data were that the PROs utilized were not developed for use in mCRPC patients and hence may not have comprehensively captured symptoms important to this population. CONCLUSIONS: Recently published randomized clinical trials of new agents for mCRPC have captured elements of the patient experience while on treatment. Further research is required to standardize methods for measuring, quantifying and reporting on HRQoL and pain in patients with mCRPC in the clinical practice setting.
format Online
Article
Text
id pubmed-4868871
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-48688712016-05-25 Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science Nussbaum, N George, D J Abernethy, A P Dolan, C M Oestreicher, N Flanders, S Dorff, T B Prostate Cancer Prostatic Dis Review BACKGROUND: Contemporary therapies for metastatic castration-resistant prostate cancer (mCRPC) have shown survival improvements, which do not account for patient experience and health-related quality of life (HRQoL). METHODS: This literature review included a search of MEDLINE for randomized clinical trials enrolling ⩾50 patients with mCRPC and reporting on patient-reported outcomes (PROs) since 2010. RESULTS: Nineteen of 25 publications describing seven treatment regimens (10 clinical trials and nine associated secondary analyses) met the inclusion criteria and were critically appraised. The most commonly used measures were the Functional Assessment of Cancer Therapy-Prostate (n=5 trials) and Brief Pain Inventory Short Form (n=4 trials) questionnaires. The published data indicated that HRQoL and pain status augmented the clinical efficacy data by providing a better understanding of treatment impact in mCRPC. Abiraterone acetate and prednisone, enzalutamide, radium-223 dichloride and sipuleucel-T offered varying levels of HRQoL benefit and/or pain mitigation versus their respective comparators, whereas three treatments (mitoxantrone, estramustine phosphate and docetaxel, and cabazitaxel) had no meaningful impact on HRQoL or pain. The main limitation of the data were that the PROs utilized were not developed for use in mCRPC patients and hence may not have comprehensively captured symptoms important to this population. CONCLUSIONS: Recently published randomized clinical trials of new agents for mCRPC have captured elements of the patient experience while on treatment. Further research is required to standardize methods for measuring, quantifying and reporting on HRQoL and pain in patients with mCRPC in the clinical practice setting. Nature Publishing Group 2016-06 2016-02-02 /pmc/articles/PMC4868871/ /pubmed/26832363 http://dx.doi.org/10.1038/pcan.2015.42 Text en Copyright © 2016 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Review
Nussbaum, N
George, D J
Abernethy, A P
Dolan, C M
Oestreicher, N
Flanders, S
Dorff, T B
Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science
title Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science
title_full Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science
title_fullStr Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science
title_full_unstemmed Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science
title_short Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science
title_sort patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868871/
https://www.ncbi.nlm.nih.gov/pubmed/26832363
http://dx.doi.org/10.1038/pcan.2015.42
work_keys_str_mv AT nussbaumn patientexperienceinthetreatmentofmetastaticcastrationresistantprostatecancerstateofthescience
AT georgedj patientexperienceinthetreatmentofmetastaticcastrationresistantprostatecancerstateofthescience
AT abernethyap patientexperienceinthetreatmentofmetastaticcastrationresistantprostatecancerstateofthescience
AT dolancm patientexperienceinthetreatmentofmetastaticcastrationresistantprostatecancerstateofthescience
AT oestreichern patientexperienceinthetreatmentofmetastaticcastrationresistantprostatecancerstateofthescience
AT flanderss patientexperienceinthetreatmentofmetastaticcastrationresistantprostatecancerstateofthescience
AT dorfftb patientexperienceinthetreatmentofmetastaticcastrationresistantprostatecancerstateofthescience